Search DARE
Dare Bioscience, Inc.
Nasdaq · CIK 1401914
Last close0.84
Daily change-0.01 (-0.94%)
10 Years gain-99.31%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
DARE · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
42.9Momentum
100.0Acceleration
100.0Confidence
73.0Annual Revenue9
Quarterly Revenue24
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth11.1 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet7.1 / 15
Shareholder Economics10.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 18711.9085 percentage points.
Net debt reductionNet debt declined versus the comparison period.
Warnings
Gross margin compression · MEDIUMGross margin compressed by 175.0949 percentage points.
Heavy share dilution · HIGHDiluted share count increased 69.9936%.
Key Metrics
Revenue Growth TTM224.8%OK
Revenue CAGR 3Y-53.12%OK
Gross Margin-75.09%OK
Operating Margin-4,194.08%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y69.99%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $1.03M | $734,394.00 | -$13.55M | -$9.89M | -$10.27M | 71.29% | -1,315.51% | -997.01% | n/a | 11.18M |
| 2025 FY Dec 31, 2024 | $9,784.00 | $9,784.00 | -$23.45M | $5.47M | $4.90M | 100% | -239,692.2% | 50,086.97% | n/a | 8.5M |
| 2024 FY Dec 31, 2023 | $2.81M | $2.81M | -$30.94M | -$38.86M | -$39.49M | 100% | -1,101.89% | -1,406.26% | n/a | 7.28M |
| 2023 FY Dec 31, 2022 | n/a | $10.00M | -$31.39M | -$18.09M | -$18.15M | n/a | n/a | n/a | n/a | 84.57M |
| 2022 FY Dec 31, 2022 | $10.00M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $321,091.00 | sum latest 4 fiscal quarters Revenue | OK | 0001401914-26-000043, 0001401914-26-000026 |
| Revenue Growth TTM | 224.8% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001401914-26-000043, 0001401914-26-000026 |
| Revenue CAGR 3Y | -53.12% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001401914-26-000004 |
| Revenue CAGR 5Y | 6.11% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001401914-26-000004 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001401914-26-000004 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001401914-26-000043, 0001401914-25-000050 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | -75.09% | Gross Profit / Revenue | OK | 0001401914-26-000043, 0001401914-26-000026 |
| Operating Margin | -4,194.08% | Operating Income / Revenue | OK | 0001401914-26-000043, 0001401914-26-000026 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001401914-26-000043 |
| Current Ratio | 0.99x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.02 | Revenue / Diluted Shares | OK | 0001401914-26-000043, 0001401914-26-000026 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001401914-26-000004 |